Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced that it will release its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Following the release, the company's management will host a conference call at 4:30 p.m. ET on the same day to review the financial results and discuss business developments during the period. Interested participants are required to register for the call using a provided link. It is recommended to join the call 10 minutes before the event, although pre-registration is available at any time. Additionally, a webcast of the call will be accessible on Kane Biotech's website in the Investor section at ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato giovedì 29 agosto 2024. Dopo il rilascio, il management dell'azienda ospiterà una telefonata di conferenza alle 16:30 ET nello stesso giorno per esaminare i risultati finanziari e discutere gli sviluppi aziendali durante il periodo. I partecipanti interessati devono registrarsi per la chiamata utilizzando un link fornito. Si raccomanda di unirsi alla chiamata 10 minuti prima dell'evento, anche se la pre-registrazione è disponibile in qualsiasi momento. Inoltre, un webcast della chiamata sarà accessibile sul sito web di Kane Biotech nella sezione Investitori su ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 después del cierre del mercado el jueves 29 de agosto de 2024. Tras la publicación, la dirección de la empresa llevará a cabo una llamada de conferencia a las 4:30 p.m. ET el mismo día para revisar los resultados financieros y discutir los desarrollos comerciales durante el periodo. Los participantes interesados deben registrarse para la llamada utilizando un enlace proporcionado. Se recomienda unirse a la llamada 10 minutos antes del evento, aunque la preinscripción está disponible en cualquier momento. Además, un webcast de la llamada será accesible en el sitio web de Kane Biotech en la sección de Inversores en ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF)는 2024년 2분기 재무 결과를 2024년 8월 29일 목요일 장 마감 후 발표할 것이라고 발표했습니다. 발표 후, 회사 경영진은 같은 날 오후 4시 30분 ET에 재무 결과를 검토하고 해당 기간 동안의 비즈니스 개발을 논의하기 위해 컨퍼런스 콜을 진행합니다. 관심 있는 참가자는 제공된 링크를 사용하여 콜에 등록해야 합니다. 이벤트 10분 전에 콜에 참여하는 것이 권장되지만, 사전 등록은 언제든지 가능합니다. 또한 전화 회의의 웹캐스트는 Kane Biotech 웹사이트의 투자자 섹션(ir.kanebiotech.com)에서 접근할 수 있습니다.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 après la clôture du marché le jeudi 29 août 2024. Suite à la publication, la direction de l'entreprise animera un appel conférence à 16h30 ET le même jour pour passer en revue les résultats financiers et discuter des développements commerciaux durant la période. Les participants intéressés doivent s'inscrire pour l'appel en utilisant un lien fourni. Il est recommandé de rejoindre l'appel 10 minutes avant l'événement, bien que la préinscription soit disponible à tout moment. De plus, un webcast de l'appel sera accessible sur le site Web de Kane Biotech dans la section Investisseur à ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) hat angekündigt, dass das Unternehmen seine Finanzergebnisse für das zweite Quartal 2024 nach Börsenschluss am Donnerstag, den 29. August 2024 veröffentlichen wird. Nach der Veröffentlichung wird das Management des Unternehmens am selben Tag um 16:30 Uhr ET eine Konferenzschaltung abhalten, um die Finanzergebnisse zu überprüfen und über geschäftliche Entwicklungen im Zeitraum zu sprechen. Interessierte Teilnehmer müssen sich über einen bereitgestellten Link für den Anruf anmelden. Es wird empfohlen, 10 Minuten vor dem Event anzurufen, obwohl eine Voranmeldung jederzeit möglich ist. Darüber hinaus wird ein Webcast der Konferenz auf der Website von Kane Biotech im Bereich für Investoren unter ir.kanebiotech.com verfügbar sein.
- None.
- None.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on Thursday, August 29, 2024.
Kane Biotech management will host a conference call at 4:30 p.m. ET on August 29, 2024 to review the financial results and discuss business developments in the period.
Participants must register for the call using this link: It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A webcast of the call will be available on Kane Biotech’s website at www.kanebiotech.com in the Investor section at ir.kanebiotech.com.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards Chief Executive Officer Kane Biotech Inc medwards@kanebiotech.com | Ray Dupuis Chief Financial Officer Kane Biotech Inc rdupuis@kanebiotech.com | |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
When will Kane Biotech (KNBIF) release its Q2 2024 financial results?
What time is Kane Biotech's (KNBIF) Q2 2024 earnings conference call?
How can I access Kane Biotech's (KNBIF) Q2 2024 earnings call?
Where can I find the webcast of Kane Biotech's (KNBIF) Q2 2024 earnings call?
